Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ AST SpaceMobile Prices Repurchase of Convertible Notes and Registered Direct Offering of Class A Common... (Business Wire) +++ AST SPACEMOBILE Aktie -3,48%

XVIVO Aktie

>XVIVO Performance
1 Woche: 0%
1 Monat: -9,0%
3 Monate: -28,6%
6 Monate: -33,0%
1 Jahr: -28,6%
laufendes Jahr: -36,7%
>XVIVO Aktie
Name:  XVIVO PERFUSION AB
Land:  Schweden
Sektor:  Gesundheit
ISIN/ Wkn:  SE0004840718 / A1J5GZ
Symbol/ Ticker:  3XV (Frankfurt)
Kürzel:  FRA:3XV, ETR:3XV, 3XV:GR
Index:  -
Webseite:  https://www.xvivoperfusio..
Marktkapitalisierung:  857.49 Mio. EUR
Umsatz:  854.98 Mio. EUR
EBITDA:  120.23 Mio. EUR
Gewinn je Aktie:  0.39 EUR
Schulden:  29.31 Mio. EUR
Liquide Mittel:  315.87 Mio. EUR
Umsatz-/ Gewinnwachstum:  17.5% / -
KGV/ KGV lG:  67.5 / 74.07
KUV/ KBV/ PEG:  10.83 / 4.4 / -
Gewinnm./ Eigenkapitalr.:  16.02% / 6.69%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  XVIVO
Letzte Datenerhebung:  25.06.25
>XVIVO Eigentümer
Aktien: 31.5 Mio. St.
f.h. Aktien: 25 Mio. St.
Insider Eigner: 9.16%
Instit. Eigner: 62.22%
Leerverk. Aktien: -
>XVIVO Peer Group

 
13.06.25 - 14:18
 XVIVO Perfusion AB: XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market (Accesswire)
 
GOTHENBURG, SWEDEN / ACCESS Newswire / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-U......
29.04.25 - 08:30
 XVIVO Perfusion AB: XVIVO Presents 12-Month Follow-Up Results from European Multicenter Heart Transplantation Trial at ISHLT in Boston (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / April 29, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - The 12-month follow-up results from XVIVO's European multicenter heart trial, NIHP2019, was p......
25.04.25 - 14:42
 Bulletin from Annual General Meeting in XVIVO Perfusion AB (Accesswire)
 
GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Per......
24.04.25 - 08:06
 XVIVO Perfusion AB: Interim Report January-March 2025 (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / April 24, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2025 (Jan-Mar)Net sales increased to SEK 218.6 million (186.0), corresponding to g......
15.04.25 - 20:42
 XVIVO Perfusion AB: Conference Call on Interim Report January-March 2025 (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.......
02.04.25 - 19:54
 XVIVO Perfusion AB: Annual Report 2024 (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / April 2, 2025 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)Today XVIVO Perfusion AB (publ) publish the Annual Report for 2024. The Annual Report is attach......
20.03.25 - 18:06
 Notice to Attend the Annual General Meeting in XVIVO Perfusion AB (Accesswire)
 
GOTHENBURG, SWEDEN / ACCESS Newswire / March 20, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives ......
28.01.25 - 08:06
 XVIVO Perfusion AB: Year-End Report 2024 (Accesswire)
 
GOTHENBURG, SE / ACCESSWIRE / January 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2024 (October 1 - December 31)• Net sales amounted to SEK 227.6 million (155.7), cor......
13.01.25 - 14:51
 XVIVO Perfusion AB: Conference Call on Year-End Report 2024 (Accesswire)
 
GOTHENBURG, SWEDEN / ACCESSWIRE / January 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report......
26.11.24 - 00:42
 XVIVO Perfusion AB: Enrollment Completed Five Months Early in the US Clinical Trial Evaluating XVIVOs Heart Preservation Technology (Accesswire)
 
GOTHENBURG, SE / ACCESSWIRE / November 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO's innovative heart technology is currently under investigation in the US clinical trial "PR......
14.11.24 - 16:32
 XVIVO Perfusion AB: XVIVO Perfusion Appoints Lena Hagman as Deputy CEO (Accesswire)
 
GOTHENBURG, SWEDEN / ACCESSWIRE / November 14, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The Board of Directors of XVIVO Perfusion AB (publ) ("XVIVO") has today appointed Lena Hagman......
24.10.24 - 08:26
 XVIVO Perfusion AB: Interim Report January-September 2024 (Accesswire)
 
GOTHENBURG, SWEDEN / ACCESSWIRE / October 24, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Third quarter 2024 (July 1 - September 30)• Net sales amounted to SEK 198.5 million (146.6), co......
10.10.24 - 14:32
 XVIVO Perfusion AB: Conference Call on Interim Report (Accesswire)
 
GOTHENBURG, SE / ACCESSWIRE / October 10, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report Janu......
19.09.24 - 15:54
 XVIVO Perfusion AB: XVIVO to Acquire a Unique Communication Platform for the Transplant Process (Accesswire)
 
GOTHENBURG, SWEDEN / ACCESSWIRE / September 19, 2024 / Today, XVIVO Perfusion AB (publ) (STO:XVIVO)(LSE:0RKL)(FRA:3XV) ("XVIVO" or "the Company") has entered into an agreement to acquire the transp......
06.09.24 - 09:43
 Nomination Committee of XVIVO Perfusion AB (Accesswire)
 
GOTHENBURG, SWEDEN / ACCESSWIRE / September 6, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following members have been appointed to XVIVO Perfusion's nomination committee for the 20......
16.08.24 - 14:54
 XVIVO Perfusion AB: Results From European Randomized Controlled Study Using XVIVO′s Heart Technology Published in The Lancet (Accesswire)
 
GOTHENBURG, SWEDEN / ACCESSWIRE / August 16, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, the results of the European randomized controlled clinical trial investigating the use o......
12.07.24 - 18:27
 Nordic Stocks Moved Upward Friday; Xvivo Perfusion Climbed Highest (Dow Jones EN)
 
Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...
12.07.24 - 08:06
 XVIVO Perfusion AB: Interim Report January - June 2024 (Accesswire)
 
GOTHENBURG, SWEDEN / ACCESSWIRE / July 12, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Second quarter 2024 (Apr 1 - Jun 30) • Net sales amounted to SEK 210.3 million (154.6), correspond......
25.06.24 - 14:31
 XVIVO Perfusion AB: Conference call on Interim Report (Accesswire)
 
GOTHENBURG, SE / ACCESSWIRE / June 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report April-J......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!